<DOC>
	<DOCNO>NCT01446185</DOCNO>
	<brief_summary>Primary objective : Determine impact Oncotype DX Recurrence Score ( RS ) treatment recommendation make ( administration chemotherapy , addition hormonotherapy ) HR+ , N- pN1 ( mi ) , Her2- breast cancer adjuvant population . The impact Oncotype DX treatment recommendation either decrease treatment intensity define change treatment recommendation chemotherapy plus hormonal therapy hormonal therapy alone increase treatment intensity define movement hormonal therapy alone addition chemotherapy hormonal therapy . Patients HR+ , N- breast cancer currently represent around 70 % newly diagnose breast cancer . These usually good prognosis tumor . However , basis classical clinical pathological prognostic parameter marker , international consensus guideline recommend treatment hormone- chemotherapy 85-95 % case . Considering natural disease history , document EBCTCG meta-analysis , 50 % patient overtreated , lead unnecessary side effect cost health system society . Oncotype DX appear well adapt therapeutic de-escalation target HR+ , N- patient perform fixed paraffin embed tissue ( FPET ) . It therefore best adapt daily clinical practice necessitate specific surgical procedure tissue freezing . The prognostic predictive value Oncotype DX ER+ , N- patient validate three large adjuvant randomize trial ( NASBP B-14 , NSABP B-20 , ATAC study ) . The test commercially available USA since 2004 , use 50 % HR+ N- patient country . While Oncotype DX validate USA , need independently evaluate France , context local treatment guideline habit , provide data meaningful French health system French medical community .</brief_summary>
	<brief_title>Treatment Decision Impact OncotypeDXâ„¢ HR+ , N- Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Patients &gt; 18 year old . 2 . Pre post menopausal woman breast adenocarcinoma , confirm pathologist underwent surgery , maximum 4 week surgery 2nd therapeutic decision Oncotype DX . 3 . HR positive ( least ER+ ) breast cancer patient ( define threshold 10 % cell IHC + without N pN1 ( mi ) , Her2 ( IHC0 , 1 , 2+ FISH ) 4 . Patients must eligible receive adjuvant chemotherapy define good Karnofsky index , hematological , cardiological hepatic contraindication impede comorbidity . 5 . Patients must give write informed consent . 1 . T3 T4 , HR , N+ ( except pN1 ( mi ) ( sn ) , Her2+ ( IHC 3+ Fish+ ) patient . 2 . Metastatic patient . 3 . Patients give informed consent . 4 . Patients receive chemotherapy . 5 . Patient participate another clinical trial still exclusion period trial . 6 . Mentally disabled patient legal responsibility .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>HR+ , N- pN1 ( mi ) , Her2- breast cancer adjuvant population</keyword>
	<keyword>Early Breast cancer</keyword>
	<keyword>Gene Expression</keyword>
	<keyword>Node-Negative</keyword>
	<keyword>treatment option</keyword>
	<keyword>Hormone receptor positive</keyword>
</DOC>